Hengrui Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Phase 1, Study to Evaluate HTI-2088 Tablet
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Hengrui Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03203811
- Locations
- 🇺🇸
Medpace, Cincinnati, Ohio, United States
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Hengrui Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02500199
- Locations
- 🇺🇸
University of California, Irvine School of Medicine, Orange, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
News
No news found